Assembly Biosciences to Present ABI-5366 Dosing and ABI-1179 Late-Breaker Data at ESCMID 2026
Assembly Biosciences will present additional monthly dosing results for ABI-5366 in an oral Phase 1b session on April 20 and interim safety and efficacy data for ABI-1179 in a late-breaker poster on April 21 at ESCMID 2026 in Munich. Posters will be posted on the company website.
1. ESCMID 2026 Presentation Schedule
Assembly Biosciences will feature two Phase 1b studies at the Congress of the European Society of Clinical Microbiology and Infectious Diseases in Munich from April 17-21, 2026. An oral presentation for ABI-5366 is scheduled for April 20 at 5:30 PM CEST, while a late-breaker poster on ABI-1179 will appear on April 21 at 12:00 PM CEST.
2. ABI-5366 Phase 1b Monthly Dosing Cohort
The oral, long-acting helicase-primase inhibitor ABI-5366 will showcase additional data from its monthly dosing cohort in participants with recurrent genital herpes. Presenters will discuss virologic analyses and safety and tolerability following repeated monthly administration in HSV-2 seropositive individuals.
3. ABI-1179 Late-Breaker Phase 1b Data
ABI-1179’s interim Phase 1b results will be presented as a late-breaker poster, highlighting safety, tolerability and antiviral activity metrics in patients with recurrent genital herpes. The data aim to demonstrate its potential as an oral, long-acting therapeutic option.
4. Data Access and Collaboration
All presentation materials will be available on the Events & Presentations and Pipeline Publications pages of the Assembly Biosciences website. Both ABI-5366 and ABI-1179 are investigational candidates licensed exclusively to Gilead Sciences, which holds responsibility for their continued development and commercialization.